Affimed to Present at the Oppenheimer 27th Annual Healthcare Conference - New York
March 15 2017 - 6:27AM
** Corrected Presentation Time **
Heidelberg, Germany, March 14, 2017 - Affimed
N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company
focused on discovering and developing highly targeted cancer
immunotherapies, announced today that Dr. Adi Hoess, CEO, will
present at the Oppenheimer 27th Annual Healthcare Conference on
Tuesday, March 21, 2017 at 4:30 p.m. (ET) in New York.
A live webcast of the conference presentation
can be accessed through the "Events" section on the "Media" page of
the Affimed website at http://www.affimed.com/events.php. A replay
of the presentation will be available from Affimed's website for 30
days following the respective conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted
immunotherapies, seeking to cure patients by harnessing the power
of innate and adaptive immunity (NK- and T-cells). We are
developing single and combination therapies to treat cancers and
other life-threatening diseases. For more information, please visit
www.affimed.com.
IR Contact:
Caroline Stewart, Head IR Phone: +1 347394 6793 E-Mail:
IR@affimed.com or c.stewart@affimed.com
Media Contact:
Anca Alexandru, Head of Communications, EU IR Phone: +49 6221
64793341 E-Mail: a.alexandru@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024